<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124514">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076373</url>
  </required_header>
  <id_info>
    <org_study_id>EpoRepair</org_study_id>
    <secondary_id>2013DR3204</secondary_id>
    <nct_id>NCT02076373</nct_id>
  </id_info>
  <brief_title>Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants</brief_title>
  <acronym>EpoRepair</acronym>
  <official_title>Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the
      effect of intravenously administered recombinant human erythropoietin (Epo) as compared to
      placebo in preterm infants with brain damage on neurological development until five years od
      age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation,
      which is more than 2 months before expected date of delivery. If these smallest infants
      suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or
      parenchymal infarction, they are at high risk for learning disabilities, mental retardation,
      and cerebral palsy in later life.

      Intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm
      infants, mostly in the very smallest and within the first few days after birth, and can be
      recorded by cranial ultrasound. Except for shunt insertion to divert cerebrospinal fluid in
      infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is
      no treatment for established intracerebral bleeding, and no medical therapies exist to
      ameliorate the neurodevelopmental sequelae.

      Apart from stimulating production of red blood cells in the bone marrow, recombinant human
      erythropoietin (Epo) has been shown to exert neuroprotective action in a variety of animal
      models and in clinical studies. Epo administration has been found to be beneficial and safe
      in randomized controlled trials (RCT) involving adult and infant patients.

      Observational data suggest that Epo administered to very preterm infants in order to prevent
      from anemia improves long-term cognitive outcomes until school-age especially in those
      infants who had suffered intracerebral bleeding. These data, however, are observational and
      therefore do not allow for any firm conclusions or recommendations. The hypothesis generated
      by these data calls for confirmation or refutation by an RCT designed to address this
      question.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>With 5 years of age, composite intelligence quotient to be assessed by standardized IQ tests. In addition, children will be classified as either being normal or having minor or major impairment according to the overall results of the tests. Children with intelligence incapable of measurement because of impairment severity will be assigned IQ scores below the lowest standard score. Normal development: All of the following: 1) Normal neurological evaluation, IQ &gt; 84; 2) No neurodevelopmental deficits. Minor impairment: One or more of the following problems: 1) Subnormal cognitive abilities (IQ, 70-84); 2) Gross and fine motor activity deficits; 3) Disorders of language development; 4) Visual and auditory deficiencies; 5) Attention disorders; 6) Abnormal socioemotional development. Major impairment: One or more of the following problems: 1) Cerebral palsy; 2) Mental retardation with IQ &lt; 70; 3)	Blindness, deafness; 4)Intractable epilepsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarker cranial MRI</measure>
    <time_frame>40 weeks postmenstrual age</time_frame>
    <safety_issue>No</safety_issue>
    <description>Brain injury score assessed on cranial MRI, including brain maturation score and white matter and gray matter injury scores, as biomarker for long-term neurodevelopmental outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Analysis will be performed to get insight about the distributions of adverse events and other safety relevant outcomes between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental outcome</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bayley Scales of Infant Development (BSID-III) and the presence or absence of impairment of motor function (cerebral palsy) and neurosensory function (blindness or deafness) will be assessed with 18 to 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker serial cranial ultrasound</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cranial ultrasound is a useful point of care method to detect, confirm and monitor brain damage including intracerebral bleeding. It is part of clinical routine for the duration of hospital stay.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Course of intracerebral bleeding</measure>
    <time_frame>Infants will be followed for the duration of hospital stay, an expected average of 14 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Course of intracerebral bleeding from onset until term equivalent age with additional visits at 28 days of life and 36 weeks postmenstrual age.
No remaining lesions as recorded by cranial ultrasound
Persisting posthemorrhagic hydrocephalus without any drainage
Persisting posthemorrhagic hydrocephalus with repetitive but transient csf-drainage
Posthemorrhagic hydrocephalus with permanent csf-drainage
Convulsions and other abnormalities or medications related to intracerebral bleeding</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intraventricular Hemorrhage of Prematurity</condition>
  <arm_group>
    <arm_group_label>recombinant human Erythropoietin (Epo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epo 2000 U per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.
In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 ml/kg of body weight 5 times intravenously, total dosage 5 ml/kg.
In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human Erythropoietin</intervention_name>
    <arm_group_label>recombinant human Erythropoietin (Epo)</arm_group_label>
    <other_name>Epoetin beta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants with less than 32 weeks of gestation and/or less than 1500 g weight at birth

          2. Intraventricular hemorrhage and/or hemorrhagic parenchymal infarction

          3. Less than 8 days of life

          4. Informed written parental consent

        Exclusion Criteria:

          1. Genetically defined syndrome

          2. Severe congenital malformation adversely affecting life expectancy and/or
             neurodevelopment

          3. A priory palliative care

          4. Unlikely to participate at 5-year follow-up examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>24 Weeks</minimum_age>
    <maximum_age>31 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Wellmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Ulrich Bucher, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Wellmann, MD</last_name>
    <phone>+41442555340</phone>
    <email>sven.wellmann@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Rüegger, MD</last_name>
    <phone>+41442555342</phone>
    <email>christoph.rueegger@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité University Medical Center</name>
      <address>
        <city>Berlin</city>
        <zip>13344</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christof Dame, MD, PhD</last_name>
      <phone>+49 30 450 566122</phone>
      <email>christof.dame@charite.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Bührer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hans Fuchs, MD</last_name>
      <phone>+4976127043000</phone>
      <email>hans.fuchs@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Roland Hentschel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Koch, MD</last_name>
      <phone>+4970712984742</phone>
      <email>Alexander.Koch@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Christian F Poets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philipp Meyer Schiffer, MD</last_name>
      <phone>+41 62 838 4948</phone>
      <email>philipp.meyer@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Philipp Meyer Schiffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Basel (UKBB)</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sven M Schulzke, MD, PhD</last_name>
      <phone>+41 61 556 5486</phone>
      <email>sven.schulzke@ukbb.ch</email>
    </contact>
    <investigator>
      <last_name>Sven M Schulzke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roland Gerull, MD</last_name>
      <phone>+41 31 632 1403</phone>
      <email>roland.gerull@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Nelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Scharrer, MD</last_name>
      <phone>+41 81 256 6406</phone>
      <email>brigitte.scharrer@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Walter Bär, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anita Truttmann, MD</last_name>
      <phone>+41213143447</phone>
      <email>Anita.Truttmann@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Jean-François Tolsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kai König, MD</last_name>
      <phone>+41 41 205 3285</phone>
      <email>kai.koenig@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Berger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ostschweizer Kinderspital</name>
      <address>
        <city>St. Gallen</city>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjarte Rogdo, MD</last_name>
      <phone>+41 71 494 1867</phone>
      <email>Bjarte.Rogdo@kispisg.ch</email>
    </contact>
    <investigator>
      <last_name>Bjarte Rogdo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Koller</last_name>
      <phone>+41442555342</phone>
      <email>brigitte.koller@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Cornelia Hagmann, MD</last_name>
      <phone>+41442555342</phone>
      <email>cornelia.hagmann@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Claude Fauchere, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.eporepair.ch</url>
    <description>EpoRepair trial homepage</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
